BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30628639)

  • 1. Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
    Li Z; Yu D; Li H; Lv Y; Li S
    Int J Oncol; 2019 Mar; 54(3):1033-1042. PubMed ID: 30628639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.
    Wu C; Luo J
    Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Corrigendum] Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
    Li Z; Yu D; Li H; Lv Y; Li S
    Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
    Lu PW; Li L; Wang F; Gu YT
    J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long non-coding RNA FOXD3 antisense RNA 1 augments anti-estrogen resistance in breast cancer cells through the microRNA-363/ trefoil factor 1/ phosphatidylinositol 3-kinase/protein kinase B axis.
    Ren L; Zhou H; Lei L; Zhang Y; Cai H; Wang X
    Bioengineered; 2021 Dec; 12(1):5266-5278. PubMed ID: 34424807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a].
    Li XN; Liu AH; Tang X; Ren Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):295-302. PubMed ID: 28416841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 inhibition sensitizes tamoxifen‑resistant breast cancer cells through cell cycle regulation.
    Chen S; Yao F; Xiao Q; Liu Q; Yang Y; Li X; Jiang G; Kuno T; Fang Y
    Mol Med Rep; 2018 Feb; 17(2):2642-2650. PubMed ID: 29207119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.
    Liu H; Wang G; Yang L; Qu J; Yang Z; Zhou X
    PLoS One; 2016; 11(12):e0168406. PubMed ID: 27977766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA UCA1 induced by SP1 promotes cell proliferation via recruiting EZH2 and activating AKT pathway in gastric cancer.
    Wang ZQ; Cai Q; Hu L; He CY; Li JF; Quan ZW; Liu BY; Li C; Zhu ZG
    Cell Death Dis; 2017 Jun; 8(6):e2839. PubMed ID: 28569779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
    Li X; Wu Y; Liu A; Tang X
    Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
    Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
    Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KDM6B Counteracts EZH2-Mediated Suppression of
    Wang W; Lim KG; Feng M; Bao Y; Lee PL; Cai Y; Chen Y; Zhang H; Marzese D; Hoon DSB; Yu Q
    Mol Cancer Ther; 2018 Sep; 17(9):1973-1983. PubMed ID: 29925528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
    Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
    Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA UCA1 elevates the resistance of human leukemia cells to daunorubicin by the PI3K/AKT pathway via sponging miR-613.
    Yao Q; Zhang L; Wang Y; Liu J; Yang L; Wang Y
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 33969374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomes mediated transfer of lncRNA UCA1 results in increased tamoxifen resistance in breast cancer cells.
    Xu CG; Yang MF; Ren YQ; Wu CH; Wang LQ
    Eur Rev Med Pharmacol Sci; 2016 Oct; 20(20):4362-4368. PubMed ID: 27831634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.
    Lu S; Du Y; Cui F; Feng X; Ma Y; Liu H
    Oncol Rep; 2019 Mar; 41(3):1901-1910. PubMed ID: 30747221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
    Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
    PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quercetin‑3‑methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K/Akt signaling pathways.
    Cao L; Yang Y; Ye Z; Lin B; Zeng J; Li C; Liang T; Zhou K; Li J
    Int J Mol Med; 2018 Sep; 42(3):1625-1636. PubMed ID: 29956731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
    Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
    Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.